VIDEO: 'Verdict still out' for mono vs. combo therapy for differentiated thyroid cancer
Click Here to Manage Email Alerts
In this video, Maria E. Cabanillas, MD, an oncologic endocrinologist at The University of Texas MD Anderson Cancer Center, discussed important research on immunotherapy combinations presented at American Thyroid Association Annual Meeting.
She discussed two studies, both evaluating combination cabozantinib (Cabometyx, Exelixis) treatment. The first evaluated cabozantinib in combination with atezolizumab (Tecentriq, Genentech) as first-line therapy in patients with radioiodine refractory differentiated thyroid cancer.
"I'm not sure if that's very different from single-agent cabozantinib and whether atezolizumab actually added anything there," Cabanillas said.
The second study evaluated cabozantinib in combination with nivolumab (Opdivo, Bristol Myers Squibb) and ipilimumab (Yervoy, Bristol Myers Squibbb) in patients with radioiodine refractory differentiated thyroid cancer after first-line VEGF receptor inhibitor failure.
"The results of this study were disappointing, and they have closed the study for enrollment because it didn't appear that combination was any better than cabozantinib alone," she said.
"In differentiated thyroid cancer, the take home is that the verdict is still out that immunotherapy adds anything," Cabanillas said.
Collapse
- Konda B, et al. Oral 44. Presented at: American Thyroid Association Annual Meeting; Oct. 19-23, 2022; Montreal.
- Taylor M, et al. Poster 100. Presented at: American Thyroid Association Annual Meeting; Oct. 19-23, 2022; Montreal.
- Healio Interviews
Click Here to Manage Email Alerts